Investors are unimpressed by Ventyx Biosciences’ bid to challenge Bristol Myers Squibb and Pfizer for the ulcerative colitis market. While the phase 2 trial hit its primary endpoint, it appears that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results